The Medipattern Corporation ("Medipattern" or the "Company") (TSX VENTURE:MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, announced today that the Company's new Visualize:Vascular(TM) continues to pinpoint patients with critical problems so that the patient can receive immediate care.

"Visualize:Vascular correctly identified a patient as having significant luminal reduction who would have never been identified using the 'standard of care' carotid Doppler Ultrasound Exam. The ultrasound results indicated slightly elevated velocities in the internal carotid artery indicative of a 50-60% stenosis but of no immediate concern. As part of our new protocol we then performed a 3D rendering of the same area with Visualize:Vascular. The 3D image generated by the software showed that the patient had significant luminal reduction which should require immediate attention. The case was discussed with the referring physicians and a Magnetic Resonance Angiogram (MRA) was ordered which confirmed that the patient had significant Stenosis requiring immediate action," stated Daniel Gurell, MD, of University Diagnostic Medical Imaging (UDMI) in Bronx, New York. "Luminal Reduction is a leading factor in determining a patient's risk of having a stroke. It can also be phrased in terms of Stenosis. If a patient measures 80 to 90% Stenosis on an angiogram, then surgery is recommended. In this case the ultrasound exam results were in the 50 to 60% range while 3D visualization and the MRA were in line with each other in the 80 to 90% range which is a huge difference, the difference between observing the patient at the next annual exam and ordering immediate surgery. The patient is being treated with surgery now. Being able to properly identify the patients who are at high risk to stroke enables the medical team consisting of the patient's cardiologist, radiologist like me and vascular surgeon to work together to prevent catastrophic strokes. Visualize:Vascular has helped us considerably with this patient and will aid us in our goal to prevent strokes before they happen."

"UDMI is committed to keeping abreast of the technological advances in radiology and to incorporating them into the practice. The practice is at the fore front of the field trying new technologies such as Medipattern's Visualize:Vascular. UDMI was the first full-service diagnostic radiology facility in the nation to earn all eight of the accreditations offered by the American College of Radiology," commented Medipattern CEO, Jeff Collins. "All of us at Medipattern are very privileged to work with Dr. Gurell and his team. We are pleased that our product was there to help make a difference. This experience helps provide another validation point along the way to show that our technology is capable of making a hugely positive impact on patient care."

Medipattern?? is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website: www.medipattern.com.

Medipattern?? is a registered mark of The Medipattern Corporation. Visualize:Vascular(TM) is a trademark of the Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential," and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.